Correspondence 0001104659-24-023235 from Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: Feb. 14, 2024 · CIK: 0001671502 · Accession: 0001104659-24-023235
AI Filing Summary & Sentiment
File numbers found in text: 333-277016
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Jessica Ansart RE: Quoin Pharmaceuticals Ltd. Registration Statement on Form S-1 File No. 333- 277016
Dear Ms. Ansart:
Quoin Pharmaceuticals Ltd. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1, as amended (File No. 333-277016), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Wednesday, February 14, 2024, at 5:30 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Murawsky (215) 569-5732 with any questions you may have concerning this request, and please notify Ms. Murawsky when this request for acceleration has been granted.
Very truly yours,
QUOIN PHARMACEUTICALS LTD.
Show Raw Text
CORRESP
1
filename1.htm
42127 Pleasant Forest Court
Ashburn, VA 20148-7349
February 14, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jessica Ansart
RE: Quoin Pharmaceuticals Ltd.
Registration Statement on
Form S-1
File No.
333- 277016
Dear Ms. Ansart:
Quoin Pharmaceuticals Ltd.
(the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1,
as amended (File No. 333-277016), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”)
to become effective on Wednesday, February 14, 2024, at 5:30 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands
that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities
under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes
Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Murawsky (215)
569-5732 with any questions you may have concerning this request, and please notify Ms. Murawsky when this request for acceleration has
been granted.
Very truly yours,
QUOIN PHARMACEUTICALS LTD.
By:
/s/ Dr. Michael Myers
Name: Dr. Michael Myers
Title: Chief Executive Officer